Forte Biosciences, Inc.
NASDAQ:FBRXBiotechnology
+$0.30 today
- Market cap
- $1.58B
- Beta
- 2.87
- P/E (TTM)
- -42.1
- EPS (TTM)
- -$0.43
Volume 0.00M
Average 0.30M
FBRX Net Receivables
Amounts owed to the company by customers and others, net of allowances for uncollectible accounts.
Forte Biosciences, Inc.NASDAQ: FBRX
Net Receivables · Q1 FY2026 · quarter ended Mar 2026
Net receivables remains negative
Q1 FY2026 net receivables was $655K, compared with $0 a year earlier.
Context
- Net receivables amounted to 1.0% of total assets at the end of Q1 FY2026, up 1.0 pp from a year earlier.
- Net receivables increased in 1 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
Sources:Balance SheetText generated from reported figures; not investment advice.
Net Receivables history
USD · from the balance sheet
- Latest · FY2025
- 817K USD
- Year-over-year change
- —
| Period | Period end | Net Receivables | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 817K | — |
| FY2024 | 2024-12-31 | 0 | — |
| FY2023 | 2023-12-31 | 0 | — |
| FY2022 | 2022-12-31 | 0 | — |
| FY2021 | 2021-12-31 | 0 | — |
Net Receivables vs competitors
How FBRX compares with its peers on the latest reported figures
- Peers report in different currencies, so net receivables is compared through growth and share of total assets rather than absolute size.
- Net receivables amounts to 1.0% of total assets for FBRX, versus a peer median of 0.0%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | CHF 2.31M CHF | -42.0% | +3.9% | 2.6% | |
| Mar 2026 | $1.7M USD | -29.2% | +15.4% | 0.5% | |
| Mar 2026 | $704K USD | -70.7% | -71.2% | 0.2% | |
| Mar 2026 | $655K USD | — | — | 1.0% | |
| Mar 2026 | $191K USD | -52.8% | -38.2% | 0.4% | |
| Mar 2026 | $0 USD | — | — | 0.0% | |
| Mar 2026 | $0 USD | — | — | 0.0% | |
| Mar 2026 | $0 USD | — | — | 0.0% | |
ELTXElicio Therapeutics, Inc. | Mar 2026 | $0 USD | — | — | 0.0% |
ACTUActuate Therapeutics Inc | Mar 2026 | $0 USD | — | — | 0.0% |
| Peer median (excluding FBRX) | — | -47.4% | -17.1% | 0.0% | |
Competitors are the stored peer set for FBRX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Forte Biosciences, Inc.
NASDAQ:FBRX
Intrinsic Alpha fair value
Locked
Current Price
$76.99
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.